Tumour biology

#Cancer research #Technology #Therapeutics #Tumour biology

First patient dosed in AVA6000 pro-Doxorubicin Phase I clinical trial

Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. The pre|CISION platform incorporates a substrate that is specifically cleaved by the protease fibroblast activation protein alpha (FAPa), which is… Read More

#News #Trending News

#Cancer immunotherapy #Cancer research #Immuno-oncology #Immunology #Tumour biology

Cancer project enters Immuno-oncology Alliance

In the UK, researchers Professor Andrew Beggs and Professor Gary Middleton from the Institute of Immunology and Immunotherapy and the Institute of Cancer and Genomic Sciences have partnered with Cancer Research UK in a target identification project for the Immuno-oncology Alliance, which translates discovery science into new therapeutics for cancer… Read More

#Cancer Research #News

#AI #Biology #R&D #Therapeutics #Tumour biology

Combining AI-driven drug capabilities with CDK targets for oncology

Exscientia and GT Apeiron Therapeutics have entered an R&D collaboration. Exscientia’s AI expertise will  be used to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. This collaboration follows the design of… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Tumour biology

First patient dosed with Gadeta’s gamma delta TCR cell therapy

Gadeta, a clinical-stage company developing gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, has announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer. The multicentre Phase I/II study in collaboration with the Dana-Farber Cancer Institute,… Read More

#Cancer Research #News

#Corning Life Sciences #Drug screening #Events #Life sciences #Tumour biology

Corning Life Sciences to host a virtual 3D Cell Culture Summit

Corning Life Sciences will be hosting a virtual 3D Cell Culture Summit, June 16-17, that will bring together industry leaders and innovators to share ideas and information, and to discuss the future of 3D applications including spheroid, organoid and tissue models 3D workflow optimisation, trends, and innovation. Some of… Read More

#News

#Cancer research #Cell and protein analysis #Tumour biology

Protein disguise could be new target for cancer immunotherapy

Researchers at the Francis Crick Institute have identified a protein that helps tumours evade the immune system and, in certain types of cancers, is linked to a poorer chance of survival. The protein could become a target for future cancer treatments. A crucial part of the immune system’s response to… Read More

#Cancer Research #News

#Biotherapeutics #Cell therapy #FDA #Tumour biology

What FDA Clearance means for GammaDelta cell cancer therapy

GammaDelta Therapeutics’ Investigational New Drug (IND) application has been cleared by the US Food and Drug Administration (FDA) for its allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies. The FDA also granted orphan drug designation to allogeneic Vδ1… Read More

#News

#Biobanking #Imaging #Immuno-oncology #Online focus #PET technology #Pharma #Phenomics #Tumour biology

Multimodal PET yields novel insights in preclinical oncology

By Mette Lauritzen PhD, Product Marketing Manager, Nuclear Molecular Imaging, Bruker BioSpin Different types of tumours, and their varying reactions to treatment, make the search for new effective cancer therapies incredibly challenging. Preclinical in vivo imaging methods are helping to obtain further knowledge of tumour morphology, progression, and biomarker expression… Read More

#Exclusive Content #News